Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,501.65 -12.72 -0.08%
S&P 500 1,875.39 -4.16 -0.22%
NASDAQ 4,126.97 -34.49 -0.83%
Ticker Volume Price Price Delta
STOXX 50 3,191.41 15.44 0.49%
FTSE 100 6,697.71 22.97 0.34%
DAX 9,590.75 46.56 0.49%
Ticker Volume Price Price Delta
NIKKEI 14,404.99 -141.28 -0.97%
TOPIX 1,164.90 -8.91 -0.76%
HANG SENG 22,554.12 44.48 0.20%

Alexza Announces Management Promotions



                    Alexza Announces Management Promotions

PR Newswire

MOUNTAIN VIEW, Calif., Aug. 1, 2013

MOUNTAIN VIEW, Calif., Aug. 1, 2013 /PRNewswire/ -- Alexza Pharmaceuticals,
Inc. (Nasdaq: ALXA) today announced the promotion of Kelly Seither to the
newly created position of Vice President, Global Strategic Marketing and New
Product Planning, and Tatjana Naranda, PhD, to the newly created position of
Vice President, Business Development and Global Alliance Management.

  o Kelly Seither joined Alexza in 2003 as Director, New Product Development
    and Market Research.  She was promoted to Senior Director, New Product
    Planning and Strategic Marketing in 2007 and to Executive Director, New
    Product Planning and Strategic Marketing in 2012.  Prior to joining
    Alexza, Ms. Seither was Senior Product Manager at Gilead Sciences from
    2002 to 2003 and Senior Product Manager at Aerogen, Inc. from 2001 to
    2002.  From 1991 to 2001, she had various positions of increasing
    responsibility at ALZA Corporation in market research, new product
    planning, sales and product management.  Ms. Seither received a BS in
    Biological Sciences from California Polytechnic State University.
  o Tatjana Naranda, PhD, joined Alexza in 2005 as Director, Business
    Development.  She was promoted to Senior Director, Business Development in
    2009 and to Executive Director, Business Development in 2012.  Prior to
    joining Alexza, Dr. Naranda was Chief Operating Officer and Chief
    Scientific Officer of Receptron, Inc., from 1998 to 2005.  Dr. Naranda
    received a PhD in Molecular Biology from the Autonomous University in
    Madrid, Spain and completed a postdoctoral fellowship in the Department of
    Biological Chemistry in the School of Medicine at UC Davis.  She received
    an MBA from Golden Gate University, a BSc in Chemistry and an MSc in
    Biochemistry from the University of Zagreb in Croatia. 

About Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals is focused on the research, development and
commercialization of novel, proprietary products for the acute treatment of
central nervous system conditions.  Alexza's products are based on the
Staccato^® system, a hand-held inhaler designed to deliver a drug aerosol to
the deep lung, providing rapid systemic delivery and therapeutic onset, in a
simple, non-invasive manner.

ADASUVE (Staccato loxapine) is Alexza's first commercial product, which was
approved by the U.S. Food and Drug Administration in December 2012 and by the
European Commission in February 2013.  Teva Pharmaceutical USA, Inc. is
Alexza's commercial partner for ADASUVE in the U.S.  Grupo Ferrer
Internacional, S.A. is Alexza's commercial partner for ADASUVE in Europe,
Latin America, Russia and the Commonwealth of Independent States countries.

For more information about Alexza, the Staccato system technology or the
Company's development programs, please visit www.alexza.com. 

ADASUVE^® and Staccato^® are registered trademarks of Alexza Pharmaceuticals,
Inc.

SOURCE Alexza Pharmaceuticals, Inc.

Website: http://www.alexza.com
Contact: Karen L. Bergman, +1-650-575-1509, kbergman@bccpartners.com, and
Michelle Corral, +1-415-794-8662, mcorral@bccpartners.com, both of BCC
Partners
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement